Myelofibrosis
Drug research and approvals for myelofibrosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 101 studies of myelofibrosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 37 drug trials for it since 2013, FDA has 5 approved and 22 open orphan designations naming it, and the EU has 5 authorised medicines for it.
- Recruiting worldwide: 101
- Trials authorized in Canada: 37
- FDA orphan approvals: 5
- EU medicines: 5
Recruiting Now
Newest start dates first, of 101 recruiting on ClinicalTrials.gov ↗- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasNCT07447817 · Phase 2 · John Mascarenhas · starts Oct 23, 2026
- An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the…NCT07883382 · Phase 1 / Phase 2 · Ruijin Hospital · starts Oct 15, 2026
- A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking RuxolitinibNCT07623161 · Phase 3 · Takeda · starts Sep 10, 2026
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in…NCT07020533 · Phase 1 · City of Hope Medical Center · starts Sep 9, 2026
- A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative NeoplasmsNCT07849231 · Phase 1 · Damora Therapeutics · starts Sep 1, 2026
- Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in MyelofibrosisNCT07521046 · Phase 1 · University of Utah · starts Aug 21, 2026
- Pacritinib Effectiveness in Real-world SettingsNCT07774455 · Not reported · Swedish Orphan Biovitrum · starts Aug 13, 2026
- TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCTNCT07302776 · Phase 1 · Stanford University · starts Jul 21, 2026
- A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With…NCT07551427 · Phase 2 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · starts Jun 18, 2026
- Study of ZE74-0282 in Patients With JAK2 V617F- or Calreticulin-Mutated Hematologic DisordersNCT07529951 · Phase 1 · Eilean Therapeutics · starts Jun 1, 2026
Trials Authorized in Canada
The 10 newest of 37; search them all in Canada trials| Jul 22, 2026 | A phase 3, double-blind, randomized trial evaluating the efficacy and safety of elritercept (tak-226) compared to placebo in participants with myelofibrosis…ELRITERCEPT (TAK-226, KER-050) | Takeda Pharmaceuticals USA | Pending |
| Mar 17, 2026 | A phase 3, randomized, double-blind, active-control study of pelabresib (dak539) and ruxolitinib vs. placebo and ruxolitinib in adult patients with…PELABRESIB (DAK539, CPI-0610) | Novartis Pharmaceuticals Corporation | Ongoing |
| Sep 17, 2025 | A phase 3, randomized, double-blind, add-on study evaluating the safety and efficacy of navtemadlin plus ruxolitinib vs placebo plus ruxolitinib in patients…NAVTEMADLIN (KRT-232) / LOPERAMIDE / ONDANSETRON | KARTOS THERAPEUTICS INC | Ongoing |
| May 1, 2025 | A randomized, double-blind, placebo-controlled multicenter phase 3 clinical study to assess efficacy and safety of ropeginterferon alfa-2b (p1101) in adult…ROPEGINTERFERON ALFA-2B-NJFT (P1101) | PharmaEssentia | Ongoing |
| Nov 28, 2024 | A phase 2 open-label study to evaluate momelotinib in combination with luspatercept in participants with transfusion dependent primary or secondary…LUSPATERCEPT / MOMELOTINIB | GSK | Ongoing |
| Nov 27, 2024 | A phase 2 multicenter study of tl-895 in subjects with myelofibrosis, indolent systemic mastocytosis, monoclonal mast cell activation syndrome, or…TL-895 (M7583) | Telios Pharmaceuticals | Ongoing |
| Jun 27, 2024 | An open label, multi-center, phase IV rollover protocol for patients who have completed a prior global novartis or incyte sponsored ruxolitinib (inc424) study…RUXOLITINIB (INC424) | Novartis Pharmaceuticals Corporation | Ongoing |
| Mar 28, 2024 | A phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with jak inhibitor-naïve myelofibrosis and moderate thrombocytopeniaSELINEXOR (KPT-330) / RUXOLITINIB / PACRITINIB | Karyopharm Therapeutics | Ongoing |
| Aug 28, 2023 | A phase 1/2, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral nuvisertib (tp-3654) in patients with intermediate or…NUVISERTIB (TP-3654) / MOMELOTINIB | Sumitomo Pharma | Pending |
| Jul 13, 2023 | A phase 1/3 study to evaluate the efficacy and safety of selinexor, a selective inhibitor of nuclear export, in combination with ruxolitinib in treatment-naïve…SELINEXOR (KPT-330) / RUXOLITINIB | Karyopharm Therapeutics | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 27| May 1, 2026 | Jakafi XRtreatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential… | Incyte Corporation | Approved |
| Sep 15, 2023 | Ojjaaratreatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and… | GlaxoSmithKline | Approved |
| Feb 28, 2022 | VonjoTreatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia)… | Sobi, Inc. | Approved |
| Aug 16, 2019 | INREBICINREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or… | Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene Corporation | Approved |
| Nov 16, 2011 | JakafiTreatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis… | Incyte Corporation | Approved |
| Dec 19, 2025 | an orally active, small molecule inhibitor of bromodomain…treatment of myelofibrosis | Opna Bio LLC | Designated |
| Dec 18, 2025 | flonoltinibtreatment of myelofibrosis | Chengdu Zenitar Biomedical Technology Co., Ltd. | Designated |
| Dec 10, 2025 | cryopreserved cord blood-derived T-regulatory cells,…treatment of myelofibrosis | cellenkos | Designated |
| Jul 8, 2025 | 3-(4-((7-cyano-1-methyl-2-((1-methyl-2-oxo-5-(trifluoromethy…treatment of myelofibrosis. | Eli Lilly and Company | Designated |
| Jan 12, 2024 | mitogen-activated protein kinase / phosphatidylinositol…Treatment of Myelofibrosis | Lympharma LLC | Designated |
| Aug 31, 2023 | 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-met…Treatment of myelofibrosis | Telios Pharma, Inc. | Designated |
| Mar 27, 2023 | parsaclisib and ruxolitinibTreatment of myelofibrosis | Incyte Corporation | Designated |
| May 26, 2022 | SelinexorTreatment of Myelofibrosis | Karyopharm Therapeutics, Inc. | Designated |
| May 16, 2022 | TasquinimodTreatment of myelofibrosis | Active Biotech AB | Designated |
| May 10, 2022 | 2-(trans-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyri…Treatment of Myelofibrosis | Sumitomo Pharma America, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Nov 12, 2026 | Ruxolitinib Zentivaruxolitinib · generic | Zentiva k.s. | EMA ↗ |
| Sep 18, 2026 | Ruxolitinib Viatrisruxolitinib hemifumarate · generic | Viatris Limited | EMA ↗ |
| Jan 25, 2024 | Omjjaramomelotinib · orphan | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| Feb 8, 2021 | Inrebicfedratinib · orphan | Bristol Myers Squibb Pharma EEIG | EMA ↗ |
| Aug 23, 2012 | Jakaviruxolitinib | Novartis Europharm Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA